⚡ Syringe Tool
Metabolic & Fat Loss FDA Approved (Specific Indications) PubChem CID: 56843331

Semaglutide: Clinical Mechanism, Dossier & Protocols

Long-acting GLP-1 receptor agonist with 94% homology to human GLP-1, featuring albumin-binding fatty acid chain for once-weekly metabolic enhancement and appetite suppression.

Reconstitution Guide Syringe Calculator BAC Water Guide

🔬 Molecular Architecture & Physical Specifications

Molecular Weight
4113.58 g/mol
Chemical Formula
C187H291N45O59
CAS Registry Number
910463-68-2
Elimination Half-Life
Approx. 7 days (168 hours)
Administration Route
Subcutaneous (SC), Oral (special SNAC formulation)
NCBI PubChem Record
Amino Acid Sequence: H-{Aib}-EGTFTSDVSSYLEGQAAK(AEEAc-AEEAc-gamma-Glu-17-carboxyheptadecanoyl)EFIAWLVRGRG

⚙️ Primary Mechanism of Action

Selectively binds GLP-1 receptors in the hypothalamus and brainstem, slowing gastric motility, dampening reward pathways for high-calorie foods, and boosting glucose-dependent insulin.

💉 Research Dosage & Reconstitution Standard

Requires pharmaceutical-grade 0.9% benzyl alcohol Bacteriostatic Water to inhibit bacterial replication for multi-dose access.

Full Step-by-Step Guide →
Standard Vial Sizes
2mg, 5mg, 10mg
Target Research Dose
0.25mg/wk (4 weeks) -> 0.5mg/wk (4 weeks) -> 1.0mg -> 1.7mg -> 2.4mg maximum
Administration Frequency
Once weekly
💧 Dilution Standard: Reconstitute with sterile Bacteriostatic Water for Injection (USP). Aim stream gently along the vial glass wall to avoid foaming. Store reconstituted solution at 2°C to 8°C (36°F to 46°F) protected from light. Discard multi-dose punctured vials at 28 days pursuant to USP <797> standards. Never freeze reconstituted liquid.

⚠️ Contraindications & Documented Adverse Effects

Strict Contraindications

  • Family/personal history of thyroid cancer (MTC/MEN2)
  • Pancreatitis

Documented Side Effects

  • Nausea
  • Burping/dyspepsia
  • Constipation
  • Fatigue
  • Headache

📚 Peer-Reviewed References & Authoritative Sources

Citations indexed in PubMed, National Center for Biotechnology Information (NCBI), and ClinicalTrials.gov.

2 VERIFIED CITATIONS
New England Journal of Medicine (NEJM 2021; 384:989-1002)
Pivotal Phase 3 trial demonstrating a mean body weight loss of 14.9% at week 68 accompanied by cardio-metabolic risk factor improvements.
PMID: 33567185 · DOI: 10.1056/NEJMoa2032183
New England Journal of Medicine (NEJM 2016; 375:1834-1844)
Multi-center randomized trial establishing a statistically significant 26% reduction in major adverse cardiovascular events (MACE).
PMID: 27633186 · DOI: 10.1056/NEJMoa1607141

⚖️ Head-to-Head Comparisons Featuring Semaglutide

Tirzepatide vs Semaglutide: Dual Agonist vs Single GLP-1 Efficacy

In head-to-head SURPASS-2 trials, Tirzepatide delivered statistically significant superior weight reduction (approx. 20....

Read Showdown →

Explore Related Research Modules

Access exact dilution guides, syringe unit calculators, and purity certificates for Semaglutide.

💧 Semaglutide Dilution Guide ⚡ Syringe Reconstitution Tool Bacteriostatic Water Monograph Tested Vendor Directory Cycle Cost Calculator